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 the currently recommended criteria for classifying drug efficacy are the most 
appropriate 
 a combination of confidence intervals methodologies is recommended to assess the 
uncertainty of drug efficacy estimates 
 the required number of eggs to count is proposed for different sample sizes 
 
Abstract 
Although various studies have provided novel insights into how to best design, analyze and 
interpret a fecal egg count reduction test (FECRT), it is still not straightforward to provide 
guidance that allows improving both the standardization and the analytical performance of the 
FECRT across a variety of both animal and nematode species. For example, it has been 
suggested to recommend a minimum number of eggs to be counted under the microscope (not 
eggs per gram of feces), but we lack the evidence to recommend any number of eggs that 
would allow a reliable assessment of drug efficacy. Other aspects that need further research 
are the methodology of calculating uncertainty intervals (UIs; confidence intervals in case of 
frequentist methods and credible intervals in case of Bayesian methods) and the criteria of 
classifying drug efficacy into ‘normal’, ‘suspected’ and ‘reduced’. The aim of this study is to 
provide complementary insights into the current knowledge, and to ultimately provide 
guidance in the development of new standardized guidelines for the FECRT. First, data were 
generated using a simulation in which the ‘true’ drug efficacy (TDE) was evaluated by the 
FECRT under varying scenarios of sample size, analytic sensitivity of the diagnostic 
technique, and level of both intensity and aggregation of egg excretion. Second, the obtained 
data were analyzed with the aim (i) to verify which classification criteria allow for reliable 













reliable assessment of drug efficacy (coverage of TDE) and detection of reduced drug 
efficacy, and (iii) to determine the required sample size and number of eggs counted under the 
microscope that optimizes the detection of reduced efficacy. Our results confirm that the 
currently recommended criteria for classifying drug efficacy are the most appropriate. 
Additionally, the UI methodologies we tested varied in coverage and ability to detect reduced 
drug efficacy, thus a combination of UI methodologies is recommended to assess the 
uncertainty across all scenarios of drug efficacy estimates. Finally, based on our model 
estimates we were able to determine the required number of eggs to count for each sample 
size, enabling investigators to optimize the probability of correctly classifying a theoretical 
TDE while minimizing both financial and technical resources. 
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The fecal egg count reduction test (FECRT) remains the recommended assay to assess 
anthelmintic drug efficacy against gastrointestinal nematodes in animals, and hence 
anthelmintic resistance (Kaplan and Vidyashankar, 2012). Guidelines for performing a 
FECRT were provided in the 1992 World Association for the Advancement of Veterinary 
Parasitology (WAAVP) publication on how to detect anthelmintic resistance in nematodes of 
veterinary importance (Coles et al., 1992). Since the publication of these guidelines, a variety 
of studies have provided novel insights into how to best design (e.g., Torgerson et al., 2005; 
2012; McKenna, 2006; Dobson et al., 2012; Levecke et al. 2012; Calvete and Uriarte, 2013), 
analyze (e.g., Vercruysse et al., 2001; Cabaret and Berrag, 2004; Dobson et al., 2009, 
Levecke et al., 2011; Vercruysse et al., 2011; Vidyashankar et al., 2012; Calvete and Uriarte, 
2013) and interpret a FECRT (e.g., Vidyashankar et al., 2007, Torgerson et al., 2005, 2014; 
Denwood et al., 2010; Dobson et al., 2012; Lyndal-Murphy et al., 2014; Geurden et al., 2015). 
These new insights point to the need for an update of the recommendations for the FECRT.  
However, it is not straightforward to provide guidance that allows improving both the 
standardization and the performance of the FECRT across a variety of both animal and 
parasite species. For example, it is well known that the required sample size and the lower 
analytic sensitivity of the fecal egg count (FEC) method (≈ 1 / mass of feces in gram 
examined under the microscope) will depend on the underlying level (or intensity) and 
aggregation of egg excretion (Levecke et al., 2012). However, these two egg excretion 
parameters vary considerable between and within both parasite and animal species, and are 
often unknown prior the FECRT, making it difficult to recommend one study design that 
applies to all possible scenarios of egg excretion while assuring the reliable performance of a 
FECRT. An approach that may untangle this complex issue is to make recommendations on 













that has been previously applied by Dobson et al., 2012. Traditionally, the eggs counted are 
converted into eggs per gram (EPG), and those data are then used for calculating percent 
reduction in FECs and the corresponding uncertainty intervals (UI, confidence intervals in 
case of frequentist methods and credible intervals in case of Bayesian methods). However, the 
eggs counted under the microscope are the actual data recorded in a FECRT; hence it is an 
important parameter with regard to both analytical issues and study design. For example, 
when FECR is based on the pre- and post-treatment FECs of the same animals and when all 
pre- and post-treatment samples are examined applying a FEC the same analytic sensitivity, 
the formula can be reduced to the ratio of the total number of eggs counted under the 
microscope at pre- and post-treatment (see Equations 1 and 2; Supplementary Material 1). 
Additionally, the total number of eggs counted under the microscope nicely grasps the 
variations in both study design (analytic sensitivity and sample size) and host-parasite 
interactions (level and aggregation of egg excretion), and hence recommending a minimum 
number of eggs to be counted under the microscope (also dependent on the examined sample 
size) allows avoiding stringent recommendations on the other parameters. As an example, if it 
were recommended to count at least 200 eggs under the microscope across at least 10 animals 
prior treatment and if animals were excreting on average 500 EPG, one could either screen 10 
animals using a diagnostic technique with a analytic sensitivity of 25 EPG (10 animals x 500 
EPG / 25 EPG = 200 eggs) or screen 20 animals with a analytic sensitivity of 50 EPG (20 
animals x 500 EPG / 50 EPG = 200 eggs). In addition, it would also allow avoiding 
underpowered trials when egg excretion at baseline revealed to be lower as anticipated or 
when the level of egg excretion is even unknown. When we now assume that the animals 
excrete 250 EPG instead of 500 EPG, the total number of eggs at baseline would be 100 for 
both study designs (= 10 animals x 250 EPG / 25 EPG = 20 animals x 250 EPG / 50 EPG), 













point, one could easily adapt the diagnostic strategy until a sufficient number of eggs are 
counted at baseline (e.g. reexamination of the same samples with the same diagnostic 
technique would in principle double the eggs counted). Although these examples illustrate the 
elegance of recommending a minimum number of eggs to be counted under the microscope 
we currently lack the evidence to recommend the number of eggs required to yield a reliable 
assessment of drug efficacy by means of the FECRT. Lastly, it is also important to avoid 
having most eggs counted come from only few animals, and hence guidance on the allowed 
distribution of egg counts across animals is also needed. 
Other aspects of analysis and interpretation of the FECRT that need further research are the 
methodology of calculating the corresponding UIs and the criteria for classifying drug 
efficacy into ‘normal’, ‘suspected’ and ‘reduced’. The UI methodology in the current 
guidelines has two important limitations. First, it can only be applied on a randomized 
controlled study design using post-treatment counts of both treatment and control groups 
(Coles et al., 1992). This experimental design, however, has proven to be less sensitive at 
detecting reduced efficacy compared to FECRT based on pre- and post-treatment counts from 
the same animals (McKenna, 2006; Dobson et al. 2012; Calvete and Uriarte, 2013). Second, 
the uncertainty of the estimates (the UI) cannot be calculated when the observed FECR is 
100%, and hence it is impossible to draw conclusions on the reliability of the estimate 
(Denwood et al., 2010; Dobson et al., 2012; Torgerson et al., 2014). This is relevant because 
seeing no eggs following treatment does not mean the efficacy was 100%; depending on how 
many eggs were counted in the pre-treatment FECs the true efficacy may be approaching 
100%, but may never reach 100% (or be considerably less than 100%). Alternative UI 
methodologies can be applied to FECRT based on counts of the same animals (Denwood et 
al., 2010; Lyndal-Murphy et al., 2014; Torgerson et al., 2014; Levecke et al., 2015; Geurden 













of estimates when FECR is 100% (Denwood et al., 2010; Dobson et al., 2012; Torgerson et 
al., 2014; Geurden et al., 2015; Peña-Espinoza et al., 2016). However, at present these 
methodologies need further research, thus the accuracy and precision of these methods 
requires further clarification. Currently, the efficacy of an anthelmintic is classified as 
‘reduced’, ‘suspected’ and ‘normal’ based on how the obtained FECR and the lower limit 
(LL) of the 95% UI relates to established thresholds, a drug efficacy for sheep and goats being 
‘reduced’ when FECR <95% and LL of UI <90%; as ‘suspected’ when either FECR <95% or 
LL <90%, and as ‘normal’ when FECR ≥95% and LL ≥90% (Coles et al., 1992). Whether 
alternative classification criteria that are solely based on the UI (e.g. drug efficacy being 
‘reduced’ when upper limit (UL) <95%, ‘normal’ when LL ≥95%, and ‘suspected’ in any 
other cases; El-Abdellati et al., 2010) or combining both the FECR-estimate and the UI 
(Lyndal-Murphy et al., 2014; Geurden et al., 2015; ‘normal’: FECR ≥95%, UL of UI ≥95% 
and LL of UI ≥90%; ‘reduced’: FECR <95%, UL of UI <95% and LL of UI <90%; 
‘suspected’ in all other cases), or only the FECR estimate (e.g., drug efficacy being ‘reduced’ 
when FECR <90%, ‘normal’ when FECR ≥95%, and ‘suspected’ in any other cases; in 
analogy with World Health Organization, 2013) would allow for reliable detection of reduced 
drug efficacy is unclear. 
The aim of this study is to provide insights complementary to the current knowledge on how 
to design, analyze and interpret FECRTs, and to ultimately provide guidance in the 
development of new standardized guidelines for the FECRT that lead to improving both the 
standardization and the analytical performance of the FECRT across a variety of both animal 















The study consisted of two consecutive procedures. First, data were generated using a 
simulation in which the ‘true’ drug efficacy (TDE) was evaluated by the FECRT under 
varying scenarios of sample size, analytic sensitivity of the diagnostic technique and level of 
both intensity and aggregation of egg excretion. Second, the obtained data were analyzed with 
the aim (i) to verify which classification criteria allows for reliable detection of reduced drug 
efficacy, (ii) to identify the UI methodology that yields the most reliable assessment of 
precision of drug efficacy, coverage of TDE and detection of reduced drug efficacy, and (iii) 
to determine the required sample size and number of eggs counted under the microscope that 
optimizes the detection of reduced efficacy.  
 
2.1. Data generation 
Data were generated by Monte Carlo simulation using a modification of the methodology 
described by Levecke et al. (2012). First, the distribution of parasites within a virtual host 
population before treatment was defined by a negative binomial distribution. This distribution 
is determined by two parameters: the mean level of intensity (mean pre-treatment fecal egg 
counts (pre-FECs)) and aggregation of egg excretion across animals (k). Low values of k 
indicate that only few animals are excreting the majority of the eggs, high values indicate that 
egg counts are more equally distributed across the host population. From this pre-defined 
distribution representing a virtual population of animals, a random sample of 5,000 FECs was 
randomly drawn. This number of FECs was required to ensure a sufficiently large number of 
unique non-zero FEC cases. Using this method, the ‘observed’ pre-FEC will be different from 
the ‘true’ pre-FEC due to the variation (i.e. stochasticity) introduced by sampling eggs 
associated with the diagnostic technique. This component of variation was simulated using 
the Poisson distribution defined by the expected number of eggs counted (i.e. ’true’ pre-













animals found to be excreting eggs (observed pre-FEC >0) at baseline. The ‘true’ FECs after 
treatment (post-FECs) were generated from the binomial distribution with the ‘true’ pre-FECs 
as the number of trials and 1-TDE as the proportion. The observed FECs after treatment (post-
FECs) were generated as described above for the pre-FECs. Subsequently, the FECR and its 
corresponding 95% UI were determined. The FECR was calculated as described in the 
formula below (Kochapakdee, 1995, Equation 1), and is based on the arithmetic mean of pre- 
and post-FECs of the same animals    
         (Eq 1) 
FECR = 1-
arithmetic mean FEC post-treatment( )
arithmetic mean FEC pre-treatment( )
   
Given an equal number of animals and the use of an equal FEC method analytic sensitivity 
before and after treatment, this equation, as shown in Supplementary Material 1, is equivalent 
to 
          (Eq 2) 
1-








    
 
 
The 95% UI intervals were based a frequentist philosophy and were calculated applying two 
different methodologies. The first methodology (method 1) is based on the mathematical 
framework described by Levecke et al., 2015. In short, this methodology derives the variance 
of the FECR applying the Taylor method (delta method; Casella and Berger, 2001) (Equation 
3), and assumes that 1-FECR follows a Gamma distribution (Equation 4). The variance of the 














































The LL and UL of the 95% UI of FECR equal 1 - 97.5th quantile and 1 - 2.5th quantile of the 
Gamma distribution with a shape parameter γ and a scale parameter θ, respectively. Based on 
the FECR, its variance and a sample size N, one can write the two parameters of the Gamma 
distribution of 1 - FECR as 










The second methodology (method 2) is based on the 95% UI described in Coles et al., 1992, 
but accounting for correlation between individual FECs before and after treatment and 
assuming that the naturally log transformed ratio of mean post-FEC and mean pre-FEC 
follows a t-distribution with N-1 degrees of freedom (Lyndal-Murphy et al., 2014). Applying 
this methodology, the variance of the log transformed ratio equals  




Based on this variance (Equation 5) and a sample size N, the LLs and ULs of the 95% UI for 
the FECR equal  



















































































The parasite/host population parameter values chosen for mean pre-FEC (25, 50, 100, 150, 
200, 250, 500, and 1,000 EPG) and k (0.1, 0.5, 0.75, 1, 1.5 and 2) were based on previously 
conducted studies where gastrointestinal nematodes were quantified in goats (Hoste et al., 
2002), sheep (Morgan et al., 2005), cattle (El-Abdellati et al., 2010), horses, pigs and 
camelids (Laboratory of Parasitology, Faculty of Veterinary Medicine, Ghent University 
(Belgium), unpublished data). The values for analytic sensitivity represented those of four 
currently used FEC methods: FLOTAC (analytic sensitivity = 1 EPG; Cringoli et al., 2010), 
mini-FLOTAC (analytic sensitivity = 5 and 10 EPG; Cringoli, et al., 2013), FECPAK 
(analytic sensitivity = 10 and 30 EPG; www.fecpak.com) and McMaster (analytic sensitivity 
= 25 and 50 EPG) (MAFF, 1986). To reduce the number of simulations, the analytic 
sensitivity of 30 EPG represented by FECPAK was omitted. The sample sizes varied from 5 
to 25 with a step-wise interval of 5. The TDE ranged from 70 to 99% with a step-wise interval 
of 1%, resulting in 36,000 combinations (8 (mean pre-FEC) x 6 (k) x 5 (analytic sensitivity) x 
5 (sample size) x 30 (TDE)) that were each iterated 100 times. 
 
2.2. Statistical data analysis 
2.2.1. Comparison of the diagnostic performance of four classification criteria for drug 
efficacy 
Four criteria, each classifying the drug efficacy as ‘reduced’, ‘suspected’ and ‘normal’, were 
included in the comparison. The first criteria (criteria 1) refer to the current definition (Coles 













<90%, as ‘suspected’ when either FECR <95% or LL <90%, and as ‘normal’ when FECR 
≥95% and LL ≥90%. The second criteria (criteria 2) are proposed by El-Abdellati et al., 2010, 
classifying a drug efficacy as ‘reduced’ when the UL of the 95% UI is <95%, as ‘suspected’ 
when FECR <95%, but 95% is included in the UI or when FECR ≥95%, but when the LL 
<95%, and as ‘normal’ when the LL ≥95%. The third criteria (criteria 3) are proposed by 
Lyndal-Murphy 2014 and Geurden et al., 2015, classifying drugs as ‘normal’ when FECR 
≥95%, UL of UI ≥95% and lower UI ≥90%, as ‘reduced’ when FECR <95%, UL of UI <95% 
and lower UI <90%, and as ‘suspected’ in all other cases. The fourth criteria (criteria 4) 
classifies drug efficacy solely based on the observed FECR result; drug efficacy being 
‘reduced’ when the FECR <90%, ‘suspected’ when FECR ≥90% but <95%, and ‘normal’ 
FECR ≥95%. This principle of classifying is applied for the classification of efficacy of drugs 
against human parasites (Schistosoma spp., Ascaris lumbricoides, Trichuris trichiura and 
hookworms; WHO, 2013). To compare the performance of the different classification criteria, 
they were each applied on the dataset generated. Subsequently, the ability of each criteria to 
correctly classify a truly reduced and normal drug efficacy were determined. To this end, 
every TDE <95% was considered as a truly reduced efficacy, and as truly normal if ≥95%. 
The calculation of the UI was based on method 1. 
 
2.2.2. Comparison of coverage and diagnostic performance of two 95% UI methodologies 
The two methodologies for calculating 95% UIs were compared based on the coverage 
(proportion of the 95% UIs that contains the TDE; which should be 95%), and their ability to 
correctly classify a truly reduced and normal drug efficacy based on classifications criteria 1, 
2 and 3. Classification criteria 4 were not included in this comparison since it classifies drug 














2.2.3. The required samples size and number of eggs counted under the microscope 
The required sample size and number of eggs that need to be counted in order to correctly 
define a truly reduced and normal efficacy were determined. To this end, fully parameterized 
logistic regression models were fitted separately for the detection of truly reduced (sensitivity) 
and truly normal drug efficacies (specificity) with the test result based on the most reliable 
classification criteria for drug efficacy (positive/negative) as the outcome, and the TDE, the 
sample size, the number of eggs counted and all possible interaction between the variables as 
covariates. Models were built for both 95% UI methodologies. The predictive power of these 
models was evaluated by the proportion of the observed outcome that was correctly predicted 
by the model. To this end, an individual probability >0.5 was set as a positive test result, and 
negative if different. Finally, the required number of eggs to be counted for correct 
classification of drugs as ‘reduced’ and ‘normal’ in at least 95% of the cases was estimated 
based on this model for each sample size across a selected range of TDE-values (87%-89%; 
97%-99%). To this end, the probability of classifying a truly reduced or normal drug efficacy 
was estimated for a wide range of scenarios of sample size and number of eggs counted. 
 
3. Results  
3.1. Comparison of the diagnostic performance of four classification criteria for drug efficacy  
The sensitivity and the specificity of detecting a truly reduced efficacy for each of the four 
classification criteria are summarized in Table 1. As illustrated in Figure 1 the sensitivity and 
specificity varied across different values of TDE, with the probability of correctly classifying 
drug efficacy decreasing as the TDE approached the threshold of 95% (surface of grey zone 
increases). For example, when applying criteria 1, an efficacy of 70% and 99% are correctly 













whereas a drug efficacy of 95% is classified as suspected in ~40% of the cases, ~20% of the 
cases as ‘reduced’, and ~40% of the cases as ‘normal’. 
<Table 1 and Figure 1 near here> 
 
 
3.2. Comparison of coverage and diagnostic performance of two 95% UI methodologies 
3.2.1. Coverage 
Overall, the coverage was lower for method 1 (85.7%) than for method 2 (90.0%). Figure 2 
illustrates the coverage over the different TDE-values, highlighting that the coverage remains 
stable for TDE values between 70% and 90% (method 1: ~87%; method 2: ~92%), but then 
drops towards ~70% when TDE was 99%. This drop can be explained by an increasing 
number of cases of FECR equal to 100% in function of increasing TDE. When excluding 
these cases, the coverage increased as a function of TDE, ranging from 87.8 to 90.7% for 
method 1, and from 92.7% to 93.0% for method 2 (Figure 2). 
<Figure 2 near here> 
 
3.2.1. Diagnostic performance 
Figure 3 illustrates the diagnostic performance of detecting reduced efficacy based on 
classification criteria 1, 2 and 3 for both 95% UI methodologies separately. Compared to 
method 1, the sensitivity of detecting reduced efficacy was comparable for method 2, and this 
was the case for the three classification criteria (criteria 1: method 1 = 90.0% vs. method 2 = 
91.0%; criteria 2: method 1 = 80.3% vs. method 2 = 80.8%; criteria 3: method 1 = 77.1 vs. 
method 2 = 78.0%). Differences in specificity, however, were more pronounced. When 













54.2% (criteria 2), whereas this was 71.1% (criteria 1 and 3) and 44% (criteria 2) when 
applying method 2. 
<Figure 3 near here> 
3.3. The required sample size and the number of eggs to be counted under the microscope  
Based on the results described in sections 3.1. and 3.2. it was concluded that criteria 1 allowed 
for the most reliable detection of reduced efficacy (highest sensitivity and second highest 
specificity), and that neither of the UI methodologies was better than the other. Therefore, the 
required sample size and the number of eggs to be counted under the microscope were 
determined applying classification criteria 1 for the two 95% UI methodologies separately. 
For the sensitivity, the logistic regression models predicted the observed data in ~93% of the 
cases (method 1 = 93.3%, method 2 = 93.6%), and for the specificity this was 81.3% and 
76.6% for methods 1 and 2, respectively. Table 2 provides the required egg numbers required 
to correctly classify a TDE of 97%, 98% and 99% as ‘normal’ and a TDE of 87%, 88% and 
89% as ‘reduced’ with a probability of at least 95% for a sample size of 5, 10, 15, 20 and 25 
for the two different methodologies for calculating UIs. In most cases, the number of eggs to 
be counted under the microscope decreased when the sample size increased and increased 
when the TDE approached the threshold of 95%. The required egg counts for correctly 
classifying a truly reduced drug efficacy is generally higher than the number of eggs required 
for classifying a truly normal drug efficacy, but this difference in the required number of eggs 
to be counted also varies between the methods applied. For example, when applying method 
1, the model predicts that counting ~200 eggs over 15 animals allows one to classify a truly 
normal drug efficacy of 98% in 95% of the cases as ‘normal’, where as this number of eggs 
only yields a correct classification of a truly reduced efficacy of 87%. When applying method 
2, the model predicts ~200 eggs over 15 animals will also allow to classify a truly reduced 













of the cases. For UI method I, the decrease in number of eggs to be counted with increasing 
sample size was small (TDE = 97%) to absent (TDE = 89%) when the TDE approached the 
threshold of 95%. Note that we have not reported the number of eggs that allow correctly 
classifying drugs with a truly underlying efficacy between 89% and 97%, and this is because 
these numbers are logistically not feasible to be obtained under field conditions (>750 eggs). 




Despite increasing criticism of the existing WAAVP recommended guidelines for FECRT 
published almost 25 years ago in 1992, and the recent progress made on how to best design, 
analyze and interpret a FECRT, there remains a lack of important evidence to support the 
revision of the current guidelines. In this study we aimed to address this lack of evidence, 
with the goal of providing insights complementary to the current knowledge, and to ultimately 
provide guidance that allows improving both the standardization and the performance of the 
FECRT with applicability across a variety of both host and parasite species. To this end, we 
consecutively compared different classification criteria and UI methodologies. Based on the 
results obtained, we determined the required samples size and number of eggs to be counted 
under the microscope that optimize the detection of reduced efficacy.  
Our results show that a number of the parameters in the current FECRT guidelines (Coles et 
al., 1992) require modification. However, our analyses also indicate that the classification 
criteria provided in the current guidelines, based on the FECR and the LL of the 95% UI, is 
the best strategy for classifying drug efficacy. Compared to the other classification criteria for 
FECRT results, these criteria provided the highest sensitivity for detecting a truly reduced 













highest probability for correctly classifying drug efficacy of the four classification criteria 
tested. Admittedly, the thresholds put forward by Coles et al. (1992) of 95% for FECR and 
90% for the LL of the UI are somewhat arbitrary. Once efficacy falls below 99%, both the 
actual reduction in efficacy and variability come into play. If the efficacy is lower than 
expected due to random variability, then a conclusion of reduced efficacy is reasonable. Thus, 
choice of the threshold is not merely a statistical issue, but also a biological one 
(Vidyashankar et al, 2012). Consequently, any threshold chosen will be arbitrary by its very 
nature. Given the usual expected efficacies of commonly used anthelmintics of >99%, and the 
limitations of precision when performing a FECRT, the choice of 95% FECR and LL of UI of 
90% remain sensible and useful thresholds. One could increase the thresholds and improve 
specificity, or decrease the thresholds and improve sensitivity, but the inherent tradeoff makes 
it impossible to maximize both simultaneously. All four of the classification criteria tested in 
our analyses used various permutations of the 95% and 90% levels for FECR and 95% UI, 
respectively. If different thresholds were used, the measured values for sensitivity and 
specificity of each classification criteria would change, but it is likely that the same 
conclusions would be reached. Thus, the results of our analyses suggest that revision of the 
current classification criteria is not justified. 
Making recommendations on the UI methodology revealed to be less straightforward. 
Compared to the methodology based on Levecke et al., 2015, the methodology described by 
Lyndal-Murphy et al., 2014, resulted in a higher coverage of the TDE (lower LL), 
approaching the expected coverage 95%, but often failed to correctly classify a truly normal 
drug efficacy. Although this poor specificity of the methodology described by Lyndal-
Murphy et al., 2014 could be resolved by either including more animals or counting more 
eggs under the microscope (Table 2), it will come with additional costs. For example, 













requires 5 – 6 minutes/sample (Levecke et al., 2009; Barda et al., 2014; Van den Putte, 2016), 
whereas this is 12 – 13 min for Mini-FLOTAC (analytic sensitivity 5 – 10 EPG; Barda et al., 
2014; Van den Putte, 2016) and 28 – 37 min for FLOTAC (analytic sensitivity of 1 – 2 EPG; 
Speich et al., 2010). In practice additional sampling requires that the original sample material 
is preserved while the first set of counts are completed and that a decision on the necessity to 
count more samples needs to be determined at the time. In addition, these UI methodologies 
do not allow the assessment of uncertainty when the FECR equals 100% and when pre- and 
post FECs are perfectly positively correlated. To illustrate these cases in more detail we have 
worked out a toy example in Supplementary Material 2. It is important to note that the data 
used in this example are not generated using the methodology described in 2.1. Data 
generation, neither do they represent real field data, rather they are both arbitrary and 
purposively generated to clearly illustrate the limitations of each UI methodology. For 
example, although it is likely to observe a FECR 100% when pre-FECs are low and when the 
analytic sensitivity of the FEC method is high (increases false negatives), an observed perfect 
correlation between observed pre- and post-FEC is virtually unlikely to occur. A variety of 
alternative Bayesian based methodologies have been described that allow to assess the 
uncertainty around the FECR estimates in these cases, and hence to draw conclusions on the 
efficacy of the drugs (Bayescount: Denwood et al., 2010; Geurden et al., 2015; Peña-Espinoza 
et al., 2016; Jeffrey’s interval: Dobson et al., 2012: eggCounts: Torgerson et al., 2014). 
However, these methodologies too have some important limitations, which impede 
recommending one methodology to estimate the uncertainty. Jeffrey’s interval (Dobson et al., 
2012) does not account for the variation and the correlation of counts at pre- and post-
treatment, and as a consequence of this, it is not appropriate for a design based on pre- and 
post-FECs of the same animals. This is made more explicit in Supplementary Material 2, 













95% UIs when Jeffrey’s interval is applied. The implementation and the interpretation of both 
Bayescount (Denwood et al., 2010; Geurden et al., 2015; Peña-Espinoza et al., 2016) and 
eggCounts (Torgerson et al., 2014) still require a high-level knowledge on statistics, which 
poses an important obstacle for their usability. Efforts in developing web interfaces to make a 
bridge between this relatively complex framework and the end-users, who are less 
experienced in statistics, should be further encouraged (eggCounts: 
http://www.math.uzh.ch/ag/?id=252). Moreover, important differences between both 
Bayesian methodologies have recently been observed, eggCounts generally reporting more 
narrow UIs compared to those of Bayescount (Peña-Espinoza et al., 2016), and these 
discrepancies in width also became apparent in the toy example described in Supplementary 
Material 2. EggCounts did not result in wider UIs when post-FECs were swapped, suggesting 
that the UIs derived from this model may not completely reflect a true underlying variation in 
drug efficacy across animals in a paired test. Also note that earlier implementations of the 
eggCounts (before October 2016) did not provided wider UIs, even when it was assumed that 
the FECs were obtained through a randomized controlled study design using post-treatment 
counts of both treatment and control groups. The latest implementation has corrected this 
error (version 1.3; Wang et al. 2017). It is out of the scope of the current study to explain 
these observed differences both between and within Bayescount and eggCounts in more 
technical detail, but it is important to underline the potential impact of these differences on 
drawing conclusions. This is in particular when inference is drawn based on UIs, including 
but not limited to classifying drug efficacy based on FECRT. For example, Kotze and 
colleagues (2014) applied eggCounts to verify whether inclusion or exclusion of low pre-
treatment FECs (<150 EPG) would affect the FECR results in 2 human clinical trials designed 
to assess the efficacy of albendazole against hookworm infections. In one of these human 













However, the reported UIs were also unexpectedly small (see also Levecke et al., 2014 which 
applied the methodology of Levecke et al., 2015), and therefore the likelihood that UIs do not 
overlap increases. As a consequence of this, the probability of falsely rejecting the null 
hypothesis that there is no difference in FECR results may have increased. Other studies that 
applied the earlier versions of eggCounts, and hence results from unpaired designs in these 
studies may need to be interpreted with caution. These include Malrait et al. (2014), das 
Neves et al. (2015), O’ Shaughnessy et al. (2014), Balmer et al. (2015), Borges et al. (2015), 
Novobilský and Höglund (2015), and Vargas-Duarte et al. (2015). Thus, if an efficacy of 
100% is observed in a study, in order to estimate the reliability (UIs) of that result we would 
recommend to apply Bayescount (Denwood et al., 2010; Geurden et al., 2015; Peña-Espinoza 
et al., 2016), Jeffrey’s interval (Dobson et al., 2012) or eggCounts (Torgerson et al., 2014: 
http://www.math.uzh.ch/ag/?id=252) despite the limitations of these methods in other 
contexts.  
Table 2 provides the required sample size and the total number of eggs to be counted under 
the microscope across a wide range of TDE values. These values should now allow 
researchers to design their FECRT according to a wide range of field conditions and without 
prior knowledge on the egg excretion in the animals, while ensuring a good diagnostic 
performance of detecting reduced efficacy. This analysis also confirms that (i) the diagnostic 
performance of the FECRT improved as a function of sample size and the number of eggs 
counted under the microscope in almost all cases, the latter being a function of the analytic 
sensitivity of the diagnostic technique, and the intensity and aggregation of egg excretion; (ii) 
that there will always be a grey zone in which it remains unreliable to draw conclusion on the 
efficacy of drugs based on FECRT (Figure 3); and (iii) that it requires more animals and 
number of eggs to be counted to correctly classify a truly reduced drug efficacy than a truly 













counted across 15 animals a TDE down to 98% (3% point from the 95% threshold) can be 
correctly classified as normal with a probability of at least 95% (UI method 1), whereas this 
same design allows, with an equal level of confidence, classifying a drug efficacy only up to 
87% (8% point difference from the 95% threshold). This different performance in classifying 
truly reduced and normal drug efficacy can be explained by the decrease in variance of FECR 
as a function of increasing drug efficacy (see formulae for calculating variance of FECR; 
Levecke et al., 2015). As a consequence of this, one may not extrapolate the required sample 
size and number of eggs to be counted across thresholds, and this is made evident in 
Supplementary Table 1. This table reports the required sample size and number of eggs 
counted to correctly classify truly reduced drug efficacy based on FECRT when a thresholds 
of 95% (LL of UI) and 99% (FECR) are used. Not surprisingly less animals and numbers of 
eggs need to be counted to correctly classify a truly reduced efficacy using these thresholds, 
in casu counting 150 eggs across 5 animals allows correctly classifying TDEs up to 93% (6% 
point difference to 99%) as reduced in 95% of the cases. Also note the difference in required 
number of eggs to be counted between UI methods. The methodology described by Levecke 
et al., 2015 requires less eggs to be counted when sample size is small compared to the 
methodology described by Lyndal-Murphy et al., 2014, but requires more eggs when sample 
size increases. Moreover, for the UI method described by Levecke et al. (2015) the number of 
eggs to be counted increased with the sample size, but only when the TDE equaled 94%. The 
latter observation is the result of the three-way interaction in the model (TDE x sample size x 
total number of eggs counted), as omission of this interaction resulted in a decrease in the 
total number of eggs to be counted as a function of sample size across all scenarios of TDE. 
Because the fully parameterized model resulted in a significant better goodness-of-fit, we 













This study has some important limitations that need to be acknowledged. First, the 
conclusions drawn are applying prediction models on data generated through simulation. 
Although the assumptions made for data generation in this simulation have been previously 
applied in other simulation studies (Torgerson et al., 2005; Dobson et al., 2009; Lyndal-
Murphy et al. 2014) and have been proven to be valid in some animal and parasite species 
(Morgan et al., 2005; Torgerson et al., 2012), they may not fully explain the variation 
observed in real data (e.g., day-to-day variation in egg excretion; variation in egg counts of 
the same sample across laboratory technicians), and hence the required sample size and 
number of eggs counted under the microscope might be biased. Moreover, predictions were 
based on models that, not surprisingly, fail to correctly predict all the data, and hence this too 
may have an impact on the required sample size and the total number of eggs counted. 
Second, we did not consider any continuing larval development, though the impact of this 
phenomenon on the interpretation of FECRT have been researched in detail by Lyndal-
Murphy et al., 2014. Third, the conclusions drawn only apply to an experimental design in 
which FECR are based on pre- and post-FECs of the same animals. When applying a 
randomized controlled design based on post-FEC of treated and control animals, more 
animals will need to be included and more eggs will need to be counted to draw conclusions 
on the drug efficacy with an equal level of reliability. This is because the term including the 
correlation needs to be omitted from the variance equation for both method 1 and 2 (FEC are 
not correlated), and hence resulting in an increased variance. For a detailed overview of the 
different 95% UI methods across different experimental designs we refer the reader to 
Lyndal-Murphy et al., 2014.  
In conclusion, optimal interpretation of FECRT data requires the ability to distinguish 
genuine reductions in efficacy from changes in efficacy due to sampling variability. In order 













analyses to determine the optimal parameters for performing the FECRT and for analyzing 
the resulting data. This study has used such an approach in an attempt to provide insights 
complementary to the current knowledge on how to optimally design, analyze and interpret 
FECRTs, and to ultimately provide guidance that allows improving both the standardization 
and the performance of the FECRT across a variety of both animal and parasite species. Our 
results confirm that the current criteria to classify drug efficacy are the most appropriate, but 
highlights that the UI methodologies vary considerable in coverage and ability to detect a 
truly reduced drug efficacy, and that a combination of UI methodologies is recommended to 
assess the uncertainty across all possible FECRT scenarios. Finally, based on model estimates 
researchers can now determine the required number of eggs to be counted for each sample 
size allowing one to optimize the probability of correctly classifying a theoretical TDE while 
minimizing both financial and technical resources. 
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Figure 1. The cumulative probability of classifying drug efficacy as ‘normal’ (black), 
‘suspected’ (grey) and ‘reduced’ (white) based on the classification criteria described by 
Coles et al. (1992), El-Abdellati et al. (2010), Lyndal-Murphy et al. (2014) / Geurden et al. 















Figure 2. The coverage of two different methodologies to calculate 95% uncertainty intervals 
(straight line: Levecke et al., 2015; dashed line: Lyndal-Murphy et al. (2014)) over different 













right plot represents the coverage for cases for which the corresponding fecal egg count 
reduction was not 100%.  
 
 
Figure 3. The cumulative probability of classifying drug efficacy as ‘normal’ (black), 
‘suspected’ (grey) and ‘reduced’ (white) based on the classification criteria described by 
Coles et al. (1992; first column of graphs), El-Abdellati et al. (2010; second column of 
graphs) and Lyndal-Murphy et al. (2014) / Geurden et al. (2015; third column of graphs) 
applying two different 95% uncertainty intervals methodologies (top graphs: Levecke et al., 













Table 1. The sensitivity and specificity of detecting a truly reduced efficacy (true drug 
efficacy <95%) for four classification criteria for drug efficacy.  
 Sensitivity  
N = 3,000,000 
 Specificity 
N = 600,000 
n %  n % 
Criteria 1 2,697,531 90.0  487,001 81.2 
Criteria 2 2,410,086 80.3  325,146 54.2 
Criteria 3 2,312,238 77.1  487,001 81.2 
Criteria 4 2,327,736 77.6  510,165 85.0 
 
Criteria 1 classifies a drug efficacy as ‘reduced’ when FECR <95% and lower limit (LL) of 
the 95% uncertainty interval (95%UI) <90%, as ‘suspected’ when either FECR <95% or LL 
<90%, and as ‘normal’ when FECR ≥95% and LL ≥90%. The criteria 2 classifies a drug 
efficacy as ‘reduced’ when the UL of the 95%UI is <95%, as ‘suspected’ when FECR <95%, 
but 95% is included in the UI or when FECR ≥95%, but when the LL <95%, and as ‘normal’ 
when the LL ≥95%. Criteria 3 classifies drugs as ‘normal’ when FECR ≥95%, UL UI ≥95% 
and lower UI ≥90%, as ‘reduced’ when FECR <95%, UL UI <95% and lower UI <90%, and 
as ‘suspected’ in all other cases. Criteria 4 classifies drug efficacy solely based on the 
observed FECR result, drug efficacy being ‘reduced’ when the FECR <90%, ‘suspected’ 


















Table 2. The required sample size and total number of eggs to be counted under the 
microscope to correctly classify a truly reduced (true drug efficacy <95%) and normal drug 
efficacy (true drug efficacy ≥95%) with a probability of at least 95% for two different 
methodologies of calculating 95% uncertainty intervals (UIs; method 1; method 2).  
 Sample size True drug efficacy (%) 
87 88 89  97 98 99 
UI method 1        
 5 255 425 670  399 218 127 
 10 234 381 633  397 208 113 
 15 206 331 589  394 196 97 
 20 170 274 537  391 183 79 
 25 121 207 474  387 168 58 
UI method 2        
 5 300 425 670  >750 563 375 
 10 255 381 633  644 399 275 
 15 205 331 589  497 316 224 
 20 149 274 537  409 266 194 













Supplementary Material 1. Given the use of a fecal egg count (FEC) with the same analytic 
sensitivity (≈ 1 / mass of feces in grams examined) on all samples before and after treatment, 
one can deduce that the fecal egg count reduction (FECR) formula based on the pre- and post-
treatment FECs of the same animals (Kochapakdee, 1995) is equivalent to the ratio of the 
total number of eggs counted under the microscope at pre- and post-treatment.  
 
FECR = 1-
arithmetic mean FEC post-treatment( )
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